---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-002458"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:04:26.142147+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arbutus receives FDA Fast Track designation for imdusiran in chronic hepatitis B

## Summary
- FDA granted Fast Track designation for imdusiran, an investigational therapy for chronic hepatitis B.
- Imdusiran has achieved functional cure in 10 chronic HBV patients in clinical trials to date.
- Fast Track may enable Accelerated Approval, Priority Review, or Rolling Review of a BLA or NDA.
- CEO Lindsay Androski said designation validates imdusiran as an important drug candidate.

## SEC filing metadata
- accession: 0001171843-26-002458
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184326002458/0001171843-26-002458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184326002458/f8k_041426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-002458
- JSON: https://secwatch.observer/filing/0001171843-26-002458.json
- Plain text: https://secwatch.observer/filing/0001171843-26-002458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.